TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure. |
Tonix Pharmaceuticals Holding Corp. (the Company) intends to
utilize two updated investor presentations to conduct meetings
with investors, stockholders and analysts and at investor
conferences, and which the Company intends to place on its
website, which may contain non-public information.Copies of the
two presentations are filed as Exhibits 99.01 and 99.02.
The information contained in Item 7.01 of this Current Report on
Form 8-K, including Exhibits 99.01 and 99.02, is furnished to,
and shall not be deemed to be filed for the purposes of, Section
18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that section.The
information contained in Item 7.01 of this Current Report shall
not be incorporated by reference into any registration statement
or any other document filed to the Securities Act of 1933, as
amended, except as otherwise expressly stated in such filing.By
filing this Current Report on Form 8-K and furnishing the
information contained in this Item 7.01, including Exhibits 99.01
and 99.02, the Company makes no admission as to the materiality
of any such information that it is furnishing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 99.01 | Corporate Presentation by the Company for March 2017* |
| 99.02 | Short Corporate Presentation by the Company for March 2017* |
* Furnished herewith.
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Recent Trading Information
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) closed its last trading session down -0.14 at 3.98 with 343,503 shares trading hands.